Santa Barbara – October 13, 2026 -- Rona Therapeutics will receive up to $100 million in upfront and near-term milestone payments from Roche under an exclusive worldwide license for its investigational RNAi candidate targeting activin receptor-like kinase 7 (ALK7), with potential for a further $1.06 billion in milestones.